What does this video actually claim?
@mbaliskhosanagp shares her Wegovy journey, reporting a 6kg weight loss from 103kg to 97kg while adding a meal plan and cutting sugar. She credits the GLP-1 medication obtained from Lesedi Medical Centre for her "slowly melting" belly.
The creator presents a fairly typical Wegovy experience without making outrageous claims. She's transparent about combining the medication with dietary changes, which is exactly what the clinical trials tested.
Her weight loss timeline isn't specified, but the 5.8% reduction she's achieved so far falls within expected ranges for semaglutide treatment.
Does the science back up her results?
Her 6kg loss represents reasonable progress on Wegovy. The STEP 1 trial (Wilding et al., NEJM, 2021) found participants lost an average of 14.9% body weight over 68 weeks with 2.4mg semaglutide weekly.
At 5.8% weight loss, she's tracking below the trial average but within normal variation. Some participants in STEP 1 lost less than 5% of their body weight, while others exceeded 20%.
Her approach of combining Wegovy with meal planning mirrors the study protocol. All STEP trial participants received lifestyle counseling sessions every four weeks alongside medication.
The "belly melting" description, while unscientific, reflects how GLP-1 agonists can reduce visceral fat. However, spot reduction isn't how these medications work.
What did she get wrong?
The creator doesn't make significant medical errors, but her "belly melting" language suggests targeted fat loss. Semaglutide promotes overall weight reduction, not selective abdominal fat burning.
She also doesn't mention potential side effects. In STEP 1, 74.2% of participants experienced gastrointestinal events like nausea, diarrhea, or vomiting. This omission gives an incomplete picture of the Wegovy experience.
Her promotion of the specific medical center raises questions about potential compensation, though she doesn't disclose any business relationship.
What should you actually know about Wegovy?
Wegovy contains 2.4mg semaglutide weekly, starting with dose escalation from 0.25mg over 16 weeks. The medication costs around $1,300 monthly in the US without insurance coverage.
Real results take time. The STEP trials measured outcomes at 68 weeks, not weeks or months. Most participants didn't reach maximum weight loss until after one year of treatment.
Side effects are common and sometimes severe. In clinical trials, 7% of participants discontinued due to gastrointestinal problems. Rare but serious risks include pancreatitis and gallbladder disease.
The medication works best as part of comprehensive lifestyle changes, not as a standalone solution. When people stop taking semaglutide, they typically regain most of the lost weight within one year.